Newly Funded Research Grants 2024

Dr. Kathryn Bowles, University of Edinburgh

Investigating mitochondrial dysfunction as an early pathogenic mechanism of primary tauopathies, using MAPT splicing mutation iPSC-organoids

Dr. Jessica Rexach, UCLA

Defining the unique immunogenetic landscape of PSP compared to related dementias

Dr. Maura Malpetti, University of Cambridge

Blood-based fingerprints of neuroinflammation in people with PSP and CBD

Dr. Yang You, Mayo Clinic Jacksonville

Characterization of plasma-derived extracellular vesicle proteomics for biomarker development of PSP and CBD

Newly Funded Research Grants 2023

Dr. Blas Couto, Institute of Translational and Cognitive Neuroscience (INCyT), Buenos Aires, Argentina

Epidemiology and Tau Biology in a Longitudinal Cohort of Argentinian Patients with PSP and CBD

Dr. Kurt Farrell, Icahan School of Medicine at Mount Sinai, New York, NY

Understanding the Roles of Risk Loci Implicated in Genome-Wide Association Studies of PSP

Dr. Luana Fioriti, Mario Negri Institute for Pharmacological Research, Milan, Italy

Potential Therapeutic Biomarkers for Progressive Supranuclear Palsy

Dr. Joseph B. Rayman, Columbia University Irving Medical Center, New York, NY

Development of Small Molecule Inhibitors of Tau Oligomerization

Funded Research Grants 2022

Dr. Edwin Jabbari, Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, UK

Fluid markers of LRRK2 as a determinant of PSP risk and disease progression

Dr. Shu Chen, Pathology, University of Alabama, Birmingham, AL - New Pipeline Grant

Development of RT-QuIC Assays of Skin Biopsy for Early Diagnosis of PSP

Dr. Johannes Levin, Department of Neurology, LMU Hospital, Munich, Germany - New Pathway Grant

In vivo assessment of reactive astrogliosis in PSP

Dr. Naomi Visanji, Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada - New Pathway Grant

Prioritizing the in vivo modeling of Progressive Supranuclear Palsy

Dr. Sarah Hopp, Glenn Biggs Institute for Neurodegenerative Disorders, The University of Texas Health Science Center, San Antonio, TX

Harnessing Microglia to Internalize and Degrade Tau

Dr. Mikael Simons, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

Evaluation of Fluid-Based and Imaging Biomarkers for Interventional Trials in PSP

Dr. Hong Xu, Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

Understanding the Diversity of Tau Pathogenesis in PSP

Ongoing Funded Grants

Dr. Marta Olah, Department of Neurology, Columbia University, New York, NY

Identification of Microglia Phenotypes Associated with Tau Pathology in PSP and CBD

Dr. Maria Catarina Lima da Silva, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Investigation of ULK1-Based Autophagy Activators as Therapeutics for Tauopathies

Dr. Daniel H. Geschwind, Department of Neurology, UCLA, Los Angeles, CA

Dr. Daniel H. Geschwind, Department of Neurology, UCLA, Los Angeles, CA

Dr. Rachel Bailey, Center for Alzheimer's and Neurodegenerative Diseases, UT Southwestern Medical Center, Dallas, TX

Gene Replacement Therapy for Tauopathies

Dr. Franziska Hopfner, Department of Neurology, Hannover Medical School, Hannover, Germany

MicroRNA profile of isolated brain cell populations in PSP

Dr. Chao Peng, Department of Neurology, UCLA David Geffen School of Medicine, Los Angeles, California

The Role of Post-Translational Modifications on Tau Transmission in PSP

Dr. Rohan de Silva, UCL Queen Square Institute of Neurology, London, UK

Do distinct 4R-tau seeding strains cause disease heterogeneity in PSP and CBD?

Dr. Rik van der Kant, Functional Genomics Department, Vrije Universiteit Amsterdam, Amsterdam, Holland

Low-dose efavirenz as a disease-modifying intervention for primary Tauopathies

Dr. Rueben Das, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

Connecting GWAS signal in TAU Locus to Effector Variant in Tauopathies

Dr. Amanda L. Woerman, University of Massachusetts, Amherst, MA

Investigating PSP and CBD Tau Strain Biology to Support Novel Diagnostic Development

Dr. John M. Ringman, Keck School of Medicine at the University of Southern California, Los Angeles, CA

Genotyping Familial Progressive Supranuclear Palsy

Dr. David C. Butler, Neural Stem Cell Institute, Regenerative Research Foundation, Rensselaer, NY

Bifunctional Intrabodies to Lower Tau

Dr. Gal Bitan, University of California, Los Angeles

Biomarkers In Brain-Derived Blood Exosomes For Improved PSP Diagnosis

Dr. Maria-Elena Avale, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Buenos Aires, Argentina

Dissecting Neuronal Dysfunctions Under 3R:4R Tau Isoforms Imbalance